Bristol Myers Squibb (BMY) Cash from Investing Activities (QoQ) (2009 - 2026)

Bristol Myers Squibb (BMY) Cash from Investing Activities (QoQ) (2009 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 91.02%
Dec 31, 2025 14.34%
Sep 30, 2025 -259.83%
Jun 30, 2025 5.21%
Mar 31, 2025 -154.59%
Dec 31, 2024 10.50%
Sep 30, 2024 83.40%
Jun 30, 2024 93.28%
Mar 31, 2024 -1,357.50%
Dec 31, 2023 -228.29%
Sep 30, 2023 -24.62%
Jun 30, 2023 -56.67%
Mar 31, 2023 -117.31%
Dec 31, 2022 158.29%
Sep 30, 2022 -620.07%
Jun 30, 2022 -404.21%
Mar 31, 2022 -76.31%
Dec 31, 2021 141.09%
Sep 30, 2021 -642.22%
Jun 30, 2021 225.87%